Clinical Trial

HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial

Study acronym: tDCS-ALS
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality. Studies suggest that High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a technique for modulating motor cortical hyperexcitability. However, evidence on the use of HD-tDCS as a neuromodulator of the diaphragmatic motor cortex in people with ALS is inconclusive.
Protocol Amendment History 3 changes
notable Primary completion moved earlier: 2028-09-01 -> 2027-12 2026-07-21
notable Primary completion pushed: 2027-07-30 -> 2028-09-01 2026-06-30
minor Completion pushed: 2027-12 -> 2028-09-01 2026-06-30
Trial Details
NCT Number NCT06719947
Lead Sponsor Universidade Federal do Rio Grande do Norte
Collaborators: Financiadora de Estudos e Projetos
Conditions Amyotrophic Lateral Sclerosis (ALS)
Enrollment 80 participants
Start Date 2025-11-28
Primary Completion 2027-12 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-20